News for Relmada Therapeutics Inc Stock (RLMD)

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

GlobeNewsWire • Thursday

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

GlobeNewsWire • 11/14/24

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Seeking Alpha • 11/10/24

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

PRNewsWire • 11/07/24

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

GlobeNewsWire • 11/04/24

Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research • 08/12/24

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Seeking Alpha • 08/09/24

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

PRNewsWire • 08/07/24

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

GlobeNewsWire • 08/05/24

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Accesswire • 07/30/24

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Accesswire • 07/23/24

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

Accesswire • 07/23/24

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Breaches And Impacted Investors Are Encouraged To Initiate Dialogues

Accesswire • 07/19/24

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Violations And Urges Affected Investors To Start Conversations

Accesswire • 07/18/24

Relmada Therapeutics Inc Is Under Examination For Possible Securities Breaches By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate Dialogues

Accesswire • 07/17/24

The Schall Law Firm Encourages Affected Investors To Start Conversation, Relmada Therapeutics Inc Is Under Scrutiny For Potential Securities Breaches

Accesswire • 07/16/24

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Urging Impacted Investors To Initiate Dialogue

Accesswire • 07/15/24

Relmada Therapeutics Inc Under Probe By The Schall Law Firm For Possible Securities Breaches Urges Affected Investors To Start Conversation

Accesswire • 07/13/24

Potential Securities Violations By Relmada Therapeutics Inc Are Under Investigation By The Schall Law Firm Encouraging Impacted Investors To Initiate Dialogue

Accesswire • 07/12/24

Relmada Therapeutics Inc Under Scrutiny By The Schall Law Firm For Potential Securities Breaches Urging Affected Investors To Initiate Conversation

Accesswire • 07/11/24

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Impacted Investors Are Urged To Establish Dialogue

Accesswire • 07/10/24

Relmada Therapeutics Inc Is Being Probed By The Schall Law Firm For Potential Securities Breaches And Affected Investors Are Encouraged To Set Up Communication

Accesswire • 07/09/24

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Impacted Investors Are Urged To Establish Communication

Accesswire • 07/08/24

The Schall Law Firm Begins Probe Into Relmada Therapeutics Inc For Suspected Securities Violations And Promotes Investors With Losses To Get In Touch

Accesswire • 07/07/24

Investigation Into Possible Securities Infringements By Relmada Therapeutics Inc Is Being Conducted By The Schall Law Firm And It Invites Affected Investors To Reach Out

Accesswire • 07/06/24